Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells.

Head and neck squamous cell carcinoma (HNSCC) cells exposed to cisplatin (CIS) displayed a dramatic ATM-dependent phosphorylation of ΔNp63α that leads to the transcriptional regulation of downstream mRNAs. Here, we report that phospho (p)-ΔNp63α transcriptionally deregulates miRNA expression after CIS treatment. Several p-ΔNp63α-dependent microRNA species (miRNAs) were deregulated in HNSCC cells upon CIS exposure, including miR-181a, miR-519a, and miR-374a (downregulated) and miR-630 (upregulated). Deregulation of miRNA expression led to subsequent modulation of mRNA expression of several targets (TP53-S46, HIPK2, ATM, CDKN1A and 1B, CASP3, PARP1 and 2, DDIT1 and 4, BCL2 and BCL2L2, TP73, YES1, and YAP1) that are involved in the apoptotic process. Our data support the notion that miRNAs are critical downstream targets of p-ΔNp63α and mediate key pathways implicated in the response of cancer cells to chemotherapeutic drugs.

Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma.

To identify novel methylated gene promoters, we compared differential RNA expression profiles of colorectal cancer (CRC) cell lines with or without treatment of 5-aza-2'-deoxycytidine (5-aza-dC). Out of 1776 genes that were initially 'absent (that is, silenced)' by gene expression array analysis, we selected 163 genes that were increased after 5-aza-dC treatment in at least two of three CRC cell lines. The microarray results were confirmed by Reverse Transcription-PCR, and CpG island of the gene promoters were amplified and sequenced for examination of cancer-specific methylation. Among the genes identified, the deafness, autosomal dominant 5 gene, DFNA5, promoter was found to be methylated in primary tumor tissues with high frequency (65%, 65/100). Quantitative methylation-specific PCR of DFNA5 clearly discriminated primary CRC tissues from normal colon tissues (3%, 3/100). The mRNA expression of DFNA5 in four of five colon cancer tissues was significantly downregulated as compared to normal tissues. Moreover, forced expression of full-length DFNA5 in CRC cell lines markedly decreased the cell growth and colony-forming ability whereas knockdown of DFNA5 increased cell growth in culture. Our data implicate DFNA5 as a novel tumor suppressor gene in CRC and a valuable molecular marker for human cancer.

The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.

N-methyl-D-aspartate receptors (NMDARs) are the predominant excitatory neurotransmitter receptors in the mammalian brain. We found that among the three NMDARs examined (NMDAR1, NMDAR2A, NMDAR2B), only NMDAR2A was silenced in colorectal carcinoma (CRC) cell lines at basal line and reactivated by the demethylating agent, 5-aza-2'-deoxycytidine. NMDAR2A was expressed in normal colon epithelium, while expression was hardly detectable in colon cancer tissues. Promoter methylation of NMDAR2A was confirmed by bisulfite sequencing and combined bisulfite restriction analysis in the CRC cell lines and primary tumors. Quantitative methylation-specific PCR demonstrated NMDAR2A promoter hypermethylation in 82 of 100 primary human CRC, 15 of 100 normal corresponding epithelial tissues and 1 of 11 (9%) normal colon mucosa samples obtained from patients without cancer. Moreover, forced expression of full-length NMDAR2A in CRC cell lines induced apoptosis and almost abolished the ability of the cells to form colonies in culture, while NMDAR2A knockdown increased cell growth. Thus, NMDAR2A is commonly hypermethylated in primary human CRC and possesses tumor-suppressive activity.

Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis.

Activated macrophages play a central role in antitumor immunity. However, the stimuli that activate macrophages to kill tumor cells are not completely understood. Because the center of solid tumors can be hypoxic, we hypothesized that hypoxia may be an important signal in activating macrophages to kill tumor cells. Hypoxia stimulates IFN-primed macrophages to express the inducible nitric oxide synthase (NOS2) and to synthesize nitric oxide (NO). We show that this synergy between IFN and hypoxia is mediated by the direct interaction of the hypoxia inducible factor-1 (HIF-1) and IFN regulatory factor-1 (IRF-1), which are both required for the hypoxic transcription of NOS2. This interaction between HIF-1 and IRF-1 may explain the mechanism by which macrophages infiltrating into tumors are activated to express NOS2 and to produce NO, a mediator of tumor apoptosis.

p53 associates with and targets Delta Np63 into a protein degradation pathway.

A human p53 homologue, p63 (p40/p51/p73L/CUSP) that maps to the chromosomal region 3q27-29 was found to produce a variety of transcripts that encode DNA-binding proteins with and without a trans-activation domain (TA- or Delta N-, respectively). The p63 gene locus was found to be amplified in squamous cell carcinoma, and overexpression of Delta Np63 (p40) led to increased growth of transformed cells in vitro and in vivo. Moreover, p63-null mice displayed abnormal epithelial development and germ-line human mutations were found to cause ectodermal dysplasia. We now demonstrate that certain p63 isotypes form complexes with p53. p53 mutations R175H or R248W abolish the association of p53 with p63, whereas V143A or R273H has no effect. Deletion studies suggest that the DNA-binding domains of both p53 and p63 mediate the association. Overexpression of wild type but not mutant (R175H) p53 results in the caspase-dependent degradation of certain Delta Np63 proteins (p40 and Delta Np63 alpha). The association between p53 and Delta Np63 supports a previously unrecognized role for p53 in regulation of Delta Np63 stability. The ability of p53 to mediate Delta Np63 degradation may balance the capacity of Delta Np63 to accelerate tumorigenesis or to induce epithelial proliferation.

AIS is an oncogene amplified in squamous cell carcinoma.

We and others recently isolated a human p53 homologue (p40/p51/p63/p73L) and localized the gene to the distal long arm of chromosome 3. Here we sought to examine the role of p40/p73L, two variants lacking the N-terminal transactivation domain, in cancer. Fluorescent in situ hybridization (FISH) analysis revealed frequent amplification of this gene locus in primary squamous cell carcinoma of the lung and head and neck cancer cell lines. (We named this locus AIS for amplified in squamous cell carcinoma.) Furthermore, amplification of the AIS locus was accompanied by RNA and protein overexpression of a variant p68(AIS) lacking the terminal transactivation domain. Protein overexpression in primary lung tumors was limited to squamous cell carcinoma and tumors known to harbor a high frequency of p53 mutations. Overexpression of p40(AIS) in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. Our results support the idea that AIS plays an oncogenic role in human cancer.

An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity.

A variety of transcriptional and post-transcriptional mechanisms regulate the expression of the inducible nitric-oxide synthase (iNOS, or NOS2). Although neurons and endothelial cells express proteins that interact with and inhibit neuronal NOS and endothelial NOS, macrophage proteins that inhibit NOS2 have not been identified. We show that murine macrophages express a 110-kDa protein that interacts with NOS2, which we call NOS-associated protein-110 kDa (NAP110). NAP110 directly interacts with the amino terminus of NOS2, and inhibits NOS catalytic activity by preventing formation of NOS2 homodimers. Expression of NAP110 may be a mechanism by which macrophages expressing NOS2 protect themselves from cytotoxic levels of nitric oxide.

Kalirin inhibition of inducible nitric-oxide synthase.

Nitric oxide (NO) acts as a neurotransmitter. However, excess NO produced from neuronal NO synthase (nNOS) or inducible NOS (iNOS) during inflammation of the central nervous system can be neurotoxic, disrupting neurotransmitter and hormone production and killing neurons. A screen of a hippocampal cDNA library showed that a unique region of the iNOS protein interacts with Kalirin, previously identified as an interactor with a secretory granule peptide biosynthetic enzyme. Kalirin associates with iNOS in vitro and in vivo and inhibits iNOS activity by preventing the formation of iNOS homodimers. Expression of exogenous Kalirin in pituitary cells dramatically reduces iNOS inhibition of ACTH secretion. Thus Kalirin may play a neuroprotective role during inflammation of the central nervous system by inhibiting iNOS activity.

Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases.

The G401 cell line derived from a rhabdoid tumor of the kidney secretes the heparin-binding growth factors midkine and pleiotrophin. Both proteins act as mitogens for diverse cells, but only midkine serves as an autocrine mitogen for G401 tumor cells. We show that midkine specifically binds a protein or complex of molecular mass greater than 200 kDa with high affinity (Kd = 0.07 +/- 0.01 nM). Midkine, but not pleiotrophin, stimulates tyrosine phosphorylation of several cellular proteins with molecular mass of 100, 130, and 200+ kDa. Upon midkine binding, the midkine-receptor complex associates with the Janus tyrosine kinases, JAK1 and JAK2. MK stimulates tyrosine phosphorylation of JAK1, JAK2, and STAT1alpha. Our initial characterization of the midkine receptor suggests that midkine autocrine stimulation of tumor cell proliferation is mediated by a cell-surface receptor which in turn might activate the JAK/STAT pathway.

Midkine stimulates Wilms' tumor cell proliferation via its signaling receptor.

Midkine, but not pleiotrophin, is mitogenic to human Wilms' tumor cells (G401 line) in dose-dependent and time-dependent fashion. Midkine specifically binds to high affinity (Kd = 0.15 +/- 0.02 nM, 210 kDa) and low affinity receptors (Kd = 0.65 +/- 0.07 nM, 75 kDa) on G401 cell surface, that has been confirmed by cross-linking and competition experiments. In addition, midkine stimulates a tyrosine phosphorylation of several proteins with molecular weight about 110-115 kDa, 130-140 kDa and 210 kDa. These data allow us to suggest that a key point in stimulation of G401 cell proliferation is interaction of midkine to its signaling receptor.

Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.

The human interferon alpha-receptor (IFNAR gene product) is a transmembranal protein of 557 amino acids with an intracytoplasmic domain of 100 amino acids containing four tyrosines. Antibodies to a C-terminal peptide (residues 521-536) were developed which efficiently immunoprecipitate the 105 kDa IFNAR protein from detergent extracts of human cells. We show that the IFNAR protein becomes tyrosine phosphorylated within 5 min after treatment of human myeloma U266 cells with IFN-alpha 2, IFN-alpha 8 or IFN-beta. The IFNAR chain interacts with both IFN-alpha 2 and IFN-beta, as demonstrated by cross-linking. Among elements involved in signal transduction by type I IFNs, the tyrosine kinase Tyk2 but not Jak1, and the ISGF3 transcription factor subunit Stat2 (p113) but not Stat1 (p91), are found associated with the IFNAR protein. After IFN-beta treatment for 5 min, a tyrosine-phosphorylated protein of approximately 95 kDa (beta-PTyr) is found bound to IFNAR, but can be dissociated by denaturation. The beta-PTyr protein is present on the cell surface, like IFNAR, as shown by extracellular biotin tagging. The ratio of beta-PTyr to IFNAR tyrosine phosphorylation is much higher with IFN-beta than with IFN-alpha 2 or 8. Both are IFN dependent and abrogated by a monoclonal antibody which blocks IFNAR action. The beta-PTyr component may represent an important difference in the action of IFN-beta as compared with IFN-alpha in their shared receptor system.

Identification of mRNAs encoding two different soluble forms of the human interferon alpha-receptor.

Transcripts of the human IFN alpha-receptor (IFNAR) gene, lacking the transmembrane (TM) domain were found in human myeloma U266S cells, in addition to the transmembranal IFNAR cDNA. Two different cDNAs encoding such soluble IFNAR forms were identified. Form 1 has a deletion causing a frameshift toward the end of the extracellular (EC) domain predicting a tail of 7 amino acids. Form 2 has two in-frame deletions and conserves most of the intracytoplasmatic domain of IFNAR. The transcripts for the two soluble forms are still found in U266R cells which have lost the transmembranal IFNAR transcript. Human cells seem to have independent mechanisms to synthesize soluble IFN receptors, which may act as competitors outside the cells or carry IFN-mediated functions inside the cell.

The expression of virus-specific nucleotide sequences in Rous sarcoma cells.

Poly(A)-enriched virus-specific mRNAs (v-mRNA) are revealed in the subcellular fractions (nuclei, mitochondria, polyribosomes and cytosol) from chicken and hamster Rous sarcoma cells. The qualitative and quantitative differences in v-mRNA populations from permissive and non-permissive tumors are shown. The sedimentation analysis of v-mRNAs allowed to ascertain the presence of three molecular classes of v-mRNA in nuclei and cytoplasm of chicken Rous sarcoma cells (35S, 28S and 22S, and 35S, 26-28S and 20S, respectively). While two size classes (33S and 20S) are shown in hamster Rous sarcoma nuclei, only 24S v-mRNA is revealed in the cytoplasm of its tumor tissue. Thus, the oncovirus gene expression is restricted in the non-permissive tumor cells, unlike of the permissive chicken Rous sarcoma cells, both in the level of transcription, and in the processing and transfer v-mRNAs from nucleus to cytoplasm. The virus gene function peculiarities in the tumors of birds and mammals are discussed.

Provirus DNA sequences in Rous sarcoma cell genome.

Non-producer hamster and virus-producing chicken Rous sarcoma cells contain a complete avian sarcoma virus (ASV)-provirus DNA (pro-DNA). Unlike this, in normal hamster liver DNA to ASV--specific sequences are absent. Moreover, the nuclear chicken Rous sarcoma and chick embryo cell (CEC) DNA preparations contain practically all endogenous chicken virus (ECV)-specific sequences, while the hamster tumor DNA was annealed with only more than half of the ECV-RNA sequences. Thus, the pro-DNA of permissive hosts contains so-called "sarcoma-specific", "common" and "endogenous--specific" nucleotide sequences. The "sarcoma-specific" and "common" sequences are present in the hamster sarcoma pro-DNA, only. Both the pro-DNA of permissive cells and the pro-DNA of non-permissive cells consist of moderately reiterated and unique sequences. The "common" regions of pro-DNA are localized, mainly, in the unique zone, while "sarcoma-specific" and "endogenous-specific" sequences of pro-DNA - in the moderately reiterated and unique zones. The pro-DNA organization of permissive and non-permissive hosts is discussed.

Virus-specific sequences in nuclear DNA from non-producer hamster Rous sarcoma.

Proviral DNA from non-producer Rous sarcoma in Syrian hamster contains practically all the nucleotide sequences presented in 125I-labeled RNA from Rous sarcoma virus, Carr-Zilber strain. Virus-specific sequences consist of moderately reiterated and unique DNA regions. The amount of Rous sarcoma virus-specific provirus equivalents in hamster Rous sarcoma DNA is equal to 5.2 +/- 0.01. Experiments on transfection show that proviral DNA studied possesses biological activity in respect to cell transformation and virus production. The infectivity of DNA from hamster tumor does not depend on the expression of group-specific (gs) antigen in the recipient cells.

Polyadenylated RNA molecules and polyribosomes in tumours of chemical and viral origin.

The distribution of poly(A)-enriched mRNA in nuclei, mitochondira, free and membrane-bound polyribosomes from normal C3HA mouse and Syrian hamster livers and normal chicken fibroblasts has been compared with that in corresponding subcellular fractions in a transplantable, chemically induced MD hepatoma, non-virus-producer hamster and virus-producer chicken Rous sarcomas. It has been shown that the content of poly(A)-RNA is increased in all tumour fractions except in free polyribosomes. The distribution of different classes of polysomes i.e. free, membrane-bound and mitochondrial outer-membrane-associated polysomes in tumour cells was changed in comparison to that in normal cells. It is concluded that in tumours of chemical and viral origin, the observed changes in the two components of the protein-synthesizing apparatus occur simultaneously.

Nucleic acids from subcellular fractions of N-nitrosodiethylamine-induced hepatoma in mice. II. Changes in gene expression during tumor progression.

The hybridization properties of in vivo labeled nuclear and mitochondrial ribonucleic acids of an transplantable hepatoma were studied. It was shown that during tumor progression the repression of nuclear genome revelead at its early stages was replaced by the de-repression at its later stages. The hybridizability of mitochondrial RNA with nuclear DNA was not changed.

Studies of poly(A+)-RNA in mouse hepatoma and cortisone-stimulated rat liver.

The content of poly(A)-containing RNA in subcellar fractions has been investigated both in cortisone-treated rat liver and experimental hepatoma cells. The fractions included nuclei, cytoplasm, mitochondria, free and membrane-bound polyribosomes. 1) In both cases of genome activation (cortisone induction and hepatoma cells) an increase in poly(A) content of all subcellular fractions except free polyribosomes was observed. 2) Cortisone was found to induce elongation of poly(A) segments detected in both nuclei and cytoplasm. 3) An increase in the poly(A) block size also was found to be stimulated in nuclei and cytoplasm of hepatoma cells. 4) The observed elongation in poly(A) length occurred against the background of an increase of the population of of poly(A)-RNA's.

Presence of ribonucleotide sequences complementary to Rous sarcoma virus (RSV) RNA in chicken cells infected with RSV.

RNA--RNA molecular hybridization between [125I] RNA from Rous sarcoma virus virions and RNAs isolated from various subcellular fractions, i.e. nuclei, mitochondria, free and membrane-bound polyribosomes, from tumors induced by RSV in chickens resulted in the formation of RNAase-resistant hybrids only with the RNA of mitochondria and membrane-bound polysomes. The origin of complementary regions in the RNAs from these organelles is discussed.